Safety and rapid efficacy of guideline-based gender affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria.

  title={Safety and rapid efficacy of guideline-based gender affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria.},
  author={Gesine Meyer and Moritz Mayer and Antonia Mondorf and Anna Katharina Fluegel and Eva Herrmann and Joerg Bojunga},
  journal={European journal of endocrinology},
OBJECTIVE Hormone treatment is an important part of gender reassignment therapy in gender dysphoria. Previous data about efficacy and safety are commonly based on small cohorts or they comprise former cohorts under meanwhile obsolet therapy regimes. Our objective was to investigate these topics in a large cohort of individuals under guideline-based treatment. DESIGN/METHODS Cohort study of medical files of n=155 male-to-female (transwomen) and n=233 female-to-male transgender persons… 

Tables from this paper

Effects of testosterone treatment on transgender males: A single-institution study

Gender-affirming hormone therapy is an effective and safe short-term treatment in Thai transgender men and an intramuscular testosterone enanthate 250 mg every 4 weeks is an alternative masculinizing regimen with decent efficacy and safety profile.

Gender‐affirming hormone therapy: An updated literature review with an eye on the future

In recent literature, it has been found that even though mental health problems are more prevalent in trans people compared to cisgender people, less psychological difficulties occur, and life satisfaction increases with gender‐affirming hormone treatment (GAHT) for those who feel this is a necessity.

Testosterone concentrations and prescription patterns of 1% testosterone gel in transgender and gender diverse individuals

A high proportion of individuals had a nonbinary gender identity and most individuals commenced a lower dose than that typically administered to hypogonadal cisgender men, potentially related to slow or ‘partial’ masculinisation goals.

The role of androgens in transgender medicine

Risk of Venous Thromboembolism in Transgender People Undergoing Hormone Feminizing Therapy: A Prevalence Meta-Analysis and Meta-Regression Study

In AMAB population with <37.5 years undergoing estrogen therapy for less than 53 months, the risk of VTE appears to be negligible and further studies are warranted to assess whether different types and administration routes of estrogen therapy could decrease the VTE risk.

Hormonal Gender Reassignment Treatment for Gender Dysphoria.

Hormonal gender reassignment treatment should only be initiated after meticulous individual consideration, with the approval of the treating psychiatrist/psychotherapist and after extensive information of the patient by an experienced endo - crinologist.

Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study

Low-dose progesterone was not associated with changes in sleep quality, psychological distress, or breast development over 3 months follow-up, though there was significant inter-individual variability.

Estradiol Therapy in the Perioperative Period: Implications for Transgender People Undergoing Feminizing Hormone Therapy

There is a need for high-quality prospective trials evaluating the perioperative risk of estradiol therapy in trans people undergoing feminizing hormone therapy to formulate evidence-based recommendations.

Characteristics of Transgender Women Referred to Women's Heart Clinic



Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.

Current treatment modalities were effective and carried a low risk for side effects and adverse events at short-time follow-up, and side effects, adverse events, and desired clinical changes were examined.

Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review

The quality of evidence was low, given the lack of randomized clinical/controlled trials and the small sample sizes, and exogenous testosterone administration to transgender men was associated with modest increases in BMI, hemoglobin/hematocrit, and LDL‐cholesterol, and with decreases in HDL‐ch cholesterol.

Effects of Gender-Affirming Hormones on Lipid, Metabolic, and Cardiac Surrogate Blood Markers in Transgender Persons.

Studies describing a higher risk for cardiometabolic and thromboembolic morbidity and/or mortality in transgender women (but not transgender men) mainly covered data on transgender women using the now obsolete ethinyl estradiol and are no longer valid.

Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study

It is shown that, after 1 year of CHT, breast development is modest and occurs primarily in the first 6 months, and no clinical or laboratory parameters were found that predict breast development.


  • W. HembreeP. Cohen-Kettenis G. T’Sjoen
  • Medicine
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2017
This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence about the effect of sex steroids on bone health in transgender individuals.

Prospective evaluation of hematocrit in gender‐affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence

Serum hematocrit levels can be found in the reference range of the perceived gender as from 3 months after the initiation of gender‐affirming hormonal treatment.

Effects of three different testosterone formulations in female-to-male transsexual persons.

One-year testosterone administration in FtM transsexuals appears to be very safe with no differences among the testosterone formulations used and the detection of subtle or long-term differences in the effects of the three formulations may require further larger and longer term studies in this and other populations.

Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals.

The treatment of female-to-male transsexuals with long-acting testosterone undecanoate may be a feasible and safe option for testosterone augmentation in these subjects, however, monitoring of blood pressure should not be ignored during the treatment, to identify patients liable to develop hypertension.

Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.

It is concluded that cross-sex hormone treatment of male-to-female transsexuals using GnRHa and oestradiol-17beta valerate is effective, and side effects and complication rates can be reduced using the treatment regimen presented here.